Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Entyvio (vedolizumab) for the Treatment of Ulcerative Colitis and Crohn’s Disease

Drug Name (Brand / Generic)

Entyvio (vedolizumab)

Company / Licensee

Takeda Pharmaceuticals

Therapy Class

Humanised immunoglobulin G1 monoclonal antibody

Product Description

Integrin receptor antagonist

Current Indication

Ulcerative colitis and Crohn’s disease

Market Sector

Gastroenterology

Development Status

Approved in the US and Europe
Expand
Close
Close
Close

Go Top